Loading

  • June 15, 2021

Ella system is Active now! ACTivate your biomarker analyses

Fast and flexible! Translate your precious and limited samples into reliable data with the Ella™ multiplex system. Just ACT!

  • June 15, 2021

Cytokine Storm Analyses

Assessing the risk of cytokine storm is of the highest importance when developing any new immunotherapy.

Early detection and timely reporting are crucial for patient safety.

Discover how we can help you here

  • March 9, 2021

State-of-the-art flow cytometry technology

Active Biomarkers is strengthening its Flow Cytometry capabilities with Novocyte Quanteon (Agilent) technology for faster immune system analysis.

- 20 color configuration

- save precious samples & time

- sophisticated and comprehensive multi-parameter analyses

  • March 9, 2021

Good job!

We are proud to announce our recently disclosed EXCELLENT grades at the 2020 EQAPOL evaluations of ELISpot and Luminex assays.

These two grades emphasize the commitment to high-quality standards from the whole ACTIVE Team for both cell-based methods and immunoassays.

  • March 9, 2021

Discover the Gyros Technology

When it comes to assay development, matching short timelines, reliable assay performances, and cost-effectiveness is always a challenge.

In our effort to actively provide you with the best solutions for PK, ADAs, or Biomarker monitoring, we recently completed our technological platform with the Gyros XPlore technology.

  • March 9, 2021

ABL Lyon becomes Active Biomarkers!

Following its acquisition by its senior management and Turenne Santé Group, ABL Lyon has changed its name and logo, to become Active Biomarkers (see Press Release).

But our team, our spirit and our vision remain the same: transforming unique biological samples into actionable information, with a strong sense of commitment!

This important milestone would not have been possible without the continued trust of our clients. We are proud to support them in the development of future life-changing therapies to fight cancer, infectious pathogens, neurodegenerative disorders or inflammatory diseases.